Last reviewed · How we verify
NCT05605197
U87 CART in Treatment of Advanced Solid Tumor
Status unknown
Phase 1
Last updated 28 May 2024
What this trial tests
Phase 1 trial testing U87 CAR-T in Pancreatic Cancer in 12 participants. Status unknown.
Timeline
19 October 2022
Primary endpoint
31 December 2024
31 December 2024
8 October 2025
Quick facts
| Lead sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 19 October 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 8 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- U87 CAR-T — full drug profile →
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Pancreatic Cancer or Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced solid tumor .
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
T Cell Based Immunotherapy for Cancer: Approaches and Strategies.
Want MY, Bashir Z, Najar RA. · · 2023 · cited 44× · PMID 37112747 · DOI 10.3390/vaccines11040835 -
"Hurdles race for CAR T-cell therapy in digestive tract cancer".
Kronig MN, Wehrli M, Salas-Benito D, Maus MV. · · 2023 · cited 12× · PMID 37694970 · DOI 10.1111/imr.13273 -
Pancreatic Cancer: Pathogenesis and Clinical Studies.
Zhou K, Liu Y, Tang C, Zhu H. · · 2025 · cited 6× · PMID 40182139 · DOI 10.1002/mco2.70162 -
The road to overcome pancreatic cancer: Where are we?
Tirpe A, Streianu C, Isachesku E, Simon I, et al · · 2024 · cited 6× · PMID 39403527 · DOI 10.1016/j.heliyon.2024.e38196 -
Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials.
Shenoy A, Yousif A, Hussain MD. · · 2025 · cited 3× · PMID 40282495 · DOI 10.3390/cancers17081319 -
Tracking cellular therapies to optimize homing against liver metastases.
Purl MC, Shick A, Canter RJ, Judge SJ. · · 2025 · cited 1× · PMID 40636106 · DOI 10.3389/fimmu.2025.1611861 -
The immunomodulatory role of tumor-initiating cells in digestive system tumors: from mechanisms to therapy.
Zhang ZY, Zhang XF, Xu CH, Wang KH, et al · · 2025 · PMID 40777043 · DOI 10.3389/fimmu.2025.1621464
Verify or expand the search:
- PubMed search for NCT05605197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd trials
Trials by the same sponsor.
- NCT07036250 — Clinical Study of U32 in Patients With Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
- NCT07453446 — Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma · Phase 1 · recruiting
- NCT07093073 — Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma · Phase 1 · recruiting
- NCT07093086 — Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma · Phase 1 · recruiting
- NCT06614686 — U87 CAR-T in Patients With Advanced Head and Neck Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05605197 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Last refreshed: 28 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing